Did some more digging From Arrayit financial report of April 22nd 2015 and press releases of early as of 2018
"Doctors and nurses currently use 15 million CA-125 tests per year to monitor ovarian cancer, generating approximately $2 billion in worldwide revenue. Capturing 1% of the ovarian cancer monitoring market would generate $97.5 million in annual revenues for Arrayit and Avant through the manufacture and sale of 150,000 OvaDx® tests at $650 per test. Our Sunnyvale laboratories have more than adequate capacity to process 150,000 OvaDx® tests per year upon FDA approval. In addition to OvaDx®, we have a pipeline of high-value diagnostic tests based on genomics, messenger RNA profiling, and proteomics. We believe that taken to its logical extension, Arrayit technology could be used to decipher and diagnose all 6,000 human diseases, including other cancers, neurodegenerative diseases such as ALS, immunological disorders, and many others."
Due to the fulfilled clinical instrumentation contract with the United States Food and Drug Administration (FDA), it can be considered that the FDA has approved the OvaDx which can generate $97.5 million in annual revenue for Arrayit but it can be even substanitally more if the Arrayit tech can detect all 6000 human diseases.
"For the fiscal year 2014, Arrayit recorded $3.3 million in negative net income, compared to $0.38 million in negative net income for the fiscal year 2013. The increase in negative net income was primarily due to one-time expenses associated with warrant issuance and repricing of warrants."
For that year they had around $2.9 million more in negative income, but due to ONE TIME expense of warrant issuance and repricing of warrant. if it wasn't for that, my prediction on negative income would be around $0.2-$0.5 million.
"We received official compliance and a one-year membership on the upgraded OTCQB exchange."
As Mark has stated in emails to myself and most likely others, that once the financials are released during Q1-2019, Arrayit will be current and up-listed to OTCQB, which means they were needing to meet the requirements set in the deal and they may have finally met them, if mark is speaking the truth but releasing financials. Also, Avant is a spinoff of Arrayit and since avant has filed its 10-K in preparation to becoming current, it can mean that mark may stay true to his word and release financials in Q1-2019
"Indeed, the first quarter of 2015 has been a particularly dynamic period for the company. We completed a large agricultural genotyping project for an important account in Eastern Europe. We launched our new HighSeqTM DNA Labeling Kits to facilitate human genome analysis in the torrid $11.1 billion global genomics market. We reported record requests for quotes (RFQs) totalling more than $3 million on strong demand for our Life Sciences instruments and consumables. We sold a $93,000 glass consumables package to a $60 billion life sciences conglomerate. We installed a SpotBot® Extreme Microarray Printer at the world’s most valuable life sciences company."
"We visited a major molecular diagnostics company in Taiwan to discuss a $1 billion testing opportunity in Asia."
In recent tweets stating that they are sending out products to Asia, we can interpret that they have achieved this opportunity.
"Turning now to our financial projections for fiscal year 2015, we expect to report total revenues in the range of $4.5 million to $8.5 million. In terms of net income, we expect to report earnings in the range of $0.5 million to $2.5 million or approximately $0.01 to $0.05 per share."
From what many board members are considering the revenue to be around $100 million - $1 billion during the year of 2019, lets say we see around $29 million to $300 million in net income (hypothetical) we can be seeing anywhere around $0.58-$6.00 per share during the year of 2019.
Also, a press release stating that Arrayit has received approval for in-store promotion by a major retail chain and tweeting they have completed making a brochure for Walgreens, also Walgreens stating they are going to be redesigning to focus more on health can mean Arrayit received approval from Walgreens.
